耐药性特异性全般性:流行率和风险因素的元分析
Tong Jiang1, Xiaohan Zhang1, Mengwen Zhang1
1Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao 266000, China.
Epilepsy & behavior : E&B
|July 31, 2023
概括
药物耐药性影响了27%的异常性泛性 (IGE) 患者. 耐药性的关键危险因素包括精神病并发症和特定类型的发作,突出了针对性治疗的需要.
科学领域:
- 神经学 神经学
- 临床神经科学 临床神经科学
- 发病学 (Epileptology) 是一个专业的学科.
背景情况:
- 异常性普遍性 (IGE) 是一种流行性综合征,其特点是早期发作和通常有利的控制.
- 这项研究调查了耐药IGE的发病率,并确定了耐药性疾病的预测性风险因素.
- 了解这些因素对于改善长期患者的治疗结果至关重要.
结论:
- 药物耐药性是异常性普遍性的重要并发症.
- 识别和解决诸如精神病并发症和特定模式等风险因素对于管理耐火性IGE至关重要.
- 对临床和电脑学因素的进一步标准化研究是有必要的,以改进治疗策略.
相关概念视频
Arteries of the Lower Limbs
214
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
214
Seizures: Classification
419
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
419
Antiepileptic Drugs: Glutamate Antagonists
422
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
422
Antiepileptic Drugs: GABAergic Pathway Potentiators
461
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
461
Antiepileptic Drugs: Potassium Channel Activators
214
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
214
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
346
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
346


